Neurology & CNS patent intelligence

US 12357586

Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12064399

Use of cannabinoids in the treatment of epilepsy

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11951097

Methods of treating multiple sclerosis

VANDA PHARMACEUTICALS INC. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11464768

Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

ACADIA Pharmaceuticals Inc. · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3201259

MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

AB SCIENCE [FR] · Granted Thu Jun 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10987346

Iloperidone for the treatment of schizophrenia

VANDA PHARMACEUTICALS INC. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10874659

Iloperidone metabolite for use in the treatment of psychiatric disorders

VANDA PHARMACEUTICALS INC. · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10441580

Iloperidone for the treatment of schizophrenia

VANDA PHARMACEUTICALS INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9757366

Methods for the treatment of parkinson's disease psychosis using pimavanserin

ACADIA Pharmaceuticals Inc. · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9687522

Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9662322

Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

WO 2017072335

UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

AB SCIENCE [FR] · Granted Thu May 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9592207

Intranasal administration of ketamine to treat depression

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9446037

Methods for the treatment of parkinson's disease psychosis using pimavanserin

ACADIA Pharmaceuticals Inc. · Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8889627

Treatment of multiple sclerosis with combination of laquinimod and fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8759302

Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7968511

Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time)